TABLE 1.
Results for Lasmiditan, Rimegepant, Ubrogepant, and Usual Care for Triptan-Ineligible Population
| Treatment | Total Cost | QALY | Life-Years | evLYG | Hours of Pain | New Interventions Versus Usual Care | |
|---|---|---|---|---|---|---|---|
| Cost per QALY | Cost per Hour of Pain Avoided | ||||||
| Lasmiditan | $12,000 | 1.8271 | 1.95 | 1.8271 | 1,650 | $151,800 | $4.32 |
| Ubrogepant | $10,660 | 1.8295 | 1.95 | 1.8295 | 1,580 | $40,000 | $1.15 |
| Rimegepant | $10,660 | 1.8295 | 1.95 | 1.8295 | 1,570 | $39,800 | $1.15 |
| Usual care | $10,050 | 1.8142 | 1.95 | 1.8142 | 2,100 | comparator | comparator |
evLYG = equal value of life-years gained; QALY = quality-adjusted life-years.